Evidence map›Paper›PMID 38666354›Full record

ArticleRenal failure2024

Assessing the role of Chemokine (C-C motif) ligand 14 in AKI: a European consensus meeting.

Jay L Koyner, Christian Arndt, Jaume Baldira Martinez de Irujo, Sílvia Coelho, Manuel Garcia-Montesinos de la Peña, Luca di Girolamo, Michael Joannidis, Pablo Jorge-Monjas, Christian Koch, Steven Lobaz and 9 more

Open access · goldAbstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Renal failure, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Biomarkers in acute kidney injury.Annals of intensive care · 2024
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors at 19 institutions in 8 countries.

Jay L KoynerSection of Nephrology, Department of Medicine, University of Chicago, Chicago, IL, USA.
Christian ArndtAnesthesiology and Intensive Care Medicine, Philipps-Universitat Marburg Fachbereich Medizin, Marburg, Germany.
Jaume Baldira Martinez de IrujoDepartment of Critical Care Medicine, Hospital Sant Pau, Barcelona, Spain.
Sílvia CoelhoIntensive Care Department, Hospital Fernando da Fonseca EPE, Amadora, Portugal.
Manuel Garcia-Montesinos de la PeñaDepartment of Intensive Care, Navarra University Hospital, Navarra, Spain.
Luca di GirolamoDepartment of Anesthesia, Critical Care and Emergency, IRCCS Policlinico San Donato, Milan, Italy.
Michael JoannidisDivision of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical Unversity Innsbruck, Innsbruck, Austria.
Pablo Jorge-MonjasAnesthesiology and Critical Care Department, Clinic University Hospital of Valladolid, Valladolid, Spain.
Christian KochDepartment of Anesthesiology, Operative Intensive Care Medicine and Pain Therapy, Justus Liebig University of Giessen, Giessen, Germany.
Steven LobazAnaesthetics and Intensive Care, Barnsley Hospital NHS Foundation Trust, Barnsley, UK.
Alain MeyerPhysiology and Functional Exploration Service, University Hospital of Strasbourg, Strasbourg, France.
Marlies OstermannDepartment of Critical Care & Nephrology, King's College London, Guy's & St Thomas' Hospital, London, UK.
Nicoletta PerticaDivision of Nephrology, Department of Biomedical and Surgical Sciences, University Hospital of Verona, Verona, Italy.
John R ProwleCritical Care & Perioperative Medicine Research Group, William Harvey Research Institute, Queen Mary University of London, London, UK.
Jon SilversidesWellcome-Wolfson Institute for Experimental Medicine, Queen's University, Belfast, UK.
Alexander ZarbockDepartment of Anesthesiology, Intensive Care and Pain Medicine, University Hospital Münster, Münster, Germany.
Jorge EcheverriBaxter Healthcare Corporation, Deerfield, IL, USA.
Kai HarenskiBaxter Deutschland GmbH, Unterschleissheim, Germany.
Lui G ForniCritical Care Unit, Royal Surrey Hospital and School of Medicine, University of Surrey, Guildford, UK.
Barnsley Hospital NHS Foundation Trust · GBBaxter (Germany) · DEBaxter (United States) · USHospital Clínico Universitario de Valladolid · ESHospital de Sant Pau · ESHospital Prof. Dr. Fernando Fonseca · PTInnsbruck Medical University · ATIRCCS Policlinico San Donato · ITKing's College London · GBPhilipps University of Marburg · DEQueen Mary University of London · GBQueen's University Belfast · GBUniversidad de Navarra · ESUniversité de Strasbourg · FRUniversity Hospital Münster · DEUniversity of Chicago · USUniversity of Giessen · DEUniversity of Surrey · GBUniversity of Verona · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUrinary Chemokine (C-C motif) ligand 14 (CCL14) is a biomarker associated with persistent severe acute kidney injury (AKI). There is limited data to support the implementation of this AKI biomarker to guide therapeutic actions.

methodsSixteen AKI experts with clinical CCL14 experience participated in a Delphi-based method to reach consensus on when and how to potentially use CCL14. Consensus was defined as ≥ 80% agreement (participants answered with 'Yes', or three to four points on a five-point Likert Scale).

resultsKey consensus areas for CCL14 test implementation were: identifying challenges and mitigations, developing a comprehensive protocol and pairing it with a treatment plan, and defining the target population. The majority agreed that CCL14 results can help to prioritize AKI management decisions. CCL14 levels above the high cutoff (> 13 ng/mL) significantly changed the level of concern for modifying the AKI treatment plan (

conclusionReal world urinary CCL14 use appears to provide improved care options to patients at risk for persistent severe AKI. Experts believe there is a role for CCL14 in AKI management and it may potentially reduce AKI-disease burden. There is, however, an urgent need for evidence on treatment decisions and adjustments based on CCL14 results.

Indexed as

Acute Kidney InjuryBiomarkersDelphi TechniqueRenal Replacement TherapyChemokines, CCConsensusEuropeHumansBiomarkersChemokines, CCBiomarker testing experienceC‑C motif chemokine ligand 14 (CCL14)consensuscritical care nephrologypersistent acute kidney injury

Identifiers

PMID38666354
PMCPMC11057457
OpenAlexW4395672888

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.